- Home
- PULM vs GDTC Comparison
PULM vs GDTC Comparison
Compare PULM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- GDTC
- Stock Information
- Founded
- PULM 2003
- GDTC 2018
- Country
- PULM United States
- GDTC Singapore
- Employees
- PULM N/A
- GDTC N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- GDTC Health Care
- Exchange
- PULM Nasdaq
- GDTC Nasdaq
- Market Cap
- PULM 30.9M
- GDTC 29.4M
- IPO Year
- PULM N/A
- GDTC 2023
- Fundamental
- Price
- PULM $6.71
- GDTC $2.18
- Analyst Decision
- PULM
- GDTC Buy
- Analyst Count
- PULM 0
- GDTC 1
- Target Price
- PULM N/A
- GDTC $5.00
- AVG Volume (30 Days)
- PULM 22.2K
- GDTC 14.6K
- Earning Date
- PULM 03-21-2025
- GDTC 01-01-0001
- Dividend Yield
- PULM N/A
- GDTC N/A
- EPS Growth
- PULM N/A
- GDTC N/A
- EPS
- PULM N/A
- GDTC N/A
- Revenue
- PULM $7,806,000.00
- GDTC $330,254.00
- Revenue This Year
- PULM N/A
- GDTC $14.71
- Revenue Next Year
- PULM $134.88
- GDTC N/A
- P/E Ratio
- PULM N/A
- GDTC N/A
- Revenue Growth
- PULM 6.96
- GDTC N/A
- 52 Week Low
- PULM $1.68
- GDTC $1.20
- 52 Week High
- PULM $10.40
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- PULM 41.18
- GDTC 31.31
- Support Level
- PULM $7.16
- GDTC $2.17
- Resistance Level
- PULM $7.33
- GDTC $2.76
- Average True Range (ATR)
- PULM 0.53
- GDTC 0.19
- MACD
- PULM -0.11
- GDTC -0.05
- Stochastic Oscillator
- PULM 0.72
- GDTC 19.78
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.